BIOCON - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.6
| Stock Code | BIOCON | Market Cap | 70,234 Cr. | Current Price | 433 ₹ | High / Low | 440 ₹ |
| Stock P/E | 294 | Book Value | 167 ₹ | Dividend Yield | 0.12 % | ROCE | 1.92 % |
| ROE | 1.24 % | Face Value | 5.00 ₹ | DMA 50 | 391 ₹ | DMA 200 | 376 ₹ |
| Chg in FII Hold | 0.13 % | Chg in DII Hold | 2.34 % | PAT Qtr | 67.3 Cr. | PAT Prev Qtr | 111 Cr. |
| RSI | 73.2 | MACD | 17.9 | Volume | 35,22,074 | Avg Vol 1Wk | 39,46,328 |
| Low price | 328 ₹ | High price | 440 ₹ | PEG Ratio | 1.72 | Debt to equity | 0.04 |
| 52w Index | 93.5 % | Qtr Profit Var | 218 % | EPS | 0.23 ₹ | Industry PE | 31.6 |
📈 Chart & Trend Analysis: BIOCON is trading at ₹433, above both its 50 DMA (₹391) and 200 DMA (₹376), showing strong short-term momentum. RSI at 73.2 indicates overbought conditions, suggesting caution for fresh entries. MACD at 17.9 shows strong positive divergence, confirming bullish bias. Bollinger Bands place the price near the upper band, signaling potential resistance around recent highs.
📊 Volume Trends: Current volume (35,22,074) is slightly below the 1-week average (39,46,328), reflecting reduced participation despite price strength.
🔑 Support & Resistance: Strong support lies at ₹391 (50 DMA) and ₹376 (200 DMA). Resistance is near ₹440 (recent high). Optimal entry zone: ₹400–₹410. Exit/profit booking zone: ₹430–₹440.
📉 Momentum Signals: RSI suggests overheated momentum, while MACD confirms bullish strength. Short-term signals favor cautious accumulation on dips rather than chasing highs.
📌 Trend Status: The stock is trending upward but showing signs of near-term consolidation due to overbought RSI.
Positive ✅
- Price trading above both 50 DMA and 200 DMA confirms technical strength.
- DII holding increased (+2.34%), showing strong domestic institutional support.
- PEG ratio of 1.72 indicates moderate valuation relative to growth.
Limitation ⚠️
- Extremely high P/E ratio (294) compared to industry average (31.6) suggests severe overvaluation.
- Weak ROCE (1.92%) and ROE (1.24%) highlight poor capital efficiency.
- EPS at ₹0.23 is very low, limiting earnings strength.
Company Negative News ❌
- PAT declined (₹111 Cr → ₹67.3 Cr), showing earnings pressure.
- Dividend yield at 0.12% is negligible, unattractive for income investors.
Company Positive News 🌟
- DII holding increased (+2.34%), boosting investor sentiment.
- FII holding increased slightly (+0.13%), reflecting marginal foreign confidence.
Industry 🏭
- Biopharma sector continues to grow with demand for biosimilars and healthcare innovation.
- Industry P/E at 31.6 indicates moderate valuations compared to BIOCON’s premium.
Conclusion 📌
BIOCON is in a bullish uptrend, supported by technical strength but faces challenges due to weak fundamentals and extreme valuations. Strong institutional support provides stability, but earnings weakness limits upside. Optimal strategy: accumulate near ₹400–₹410 support zones and consider profit booking near ₹430–₹440. Trend remains upward but consolidation is likely in the short term.
Would you like me to extend this into a short-term intraday plan, a swing trading setup, or a long-term investment outlook?